PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
|Articles|February 19, 2014
Equipment and Processing Report
- Equipment and Processing Report-02-19-2014
- Volume 0
- Issue 0
Schreiner MediPharm Introduces SecuMed Labeling System
A combination of overt and covert features protects against counterfeiting.
Schreiner MediPharm’s SecuMed pharmaceutical labeling system offers authentication and protection against counterfeiting in a multi-step security concept. The SecuMed labeling system can be customized according to the specific requirements of pharmaceutical manufacturers. The labels can integrate a specific mix of overt, covert, and machine-readable security features. Options include complex holograms, ShiftSecure color-shifting ink, thermo-reactive print (in which colors change at various temperatures), and a covert feature known as LaserSecure, which involves invisible, machine-readable security pigments that can be integrated into all graphic elements and colors. The company will introduce the SecuMed labeling system to the North American market at INTERPHEX 2014.
Source:
Articles in this issue
over 12 years ago
Complying with Revised USP Chapters on Weighingover 12 years ago
Developments in Producing MicrospheresRelated to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Christy Owings, Thermo Fisher, on why early supply chain partnership and site visits prevent costly eCOA and clinical trial delays.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.